Freeslate, Inc. Releases New High Throughput Research Workflow for Biologics Formulation Development at BioProcess International conference

Share Article

Freeslate introduces new product for accelerating research in biologics formulation

We believe our Biologics Formulation Workflow can dramatically enhance scientific knowledge and enable scientists to make more informed decisions

Freeslate, Inc., the leading provider of high throughput research solutions, today announced the release of its Biologic Formulation Workflow, a comprehensive solution for accelerating research in vaccine and protein formulation development. The workflow automates and integrates sample preparation, sample stressing and formulation analysis allowing for exploration of a much broader experimental space with the same resources and available material. This exploration supports Quality by Design (QbD) initiatives and reduces development risk.

“We are excited to introduce this system, the first comprehensive product solution for addressing the significant industry challenges of creating stable formulations for large molecule drug products. We believe our Biologics Formulation Workflow can dramatically enhance scientific knowledge and enable scientists to make more informed decisions when addressing the challenges of aggregation and particulation in vaccines and protein therapeutics,” said John Senaldi, CEO of Freeslate. “This is an application area where our solutions can help organizations realize dramatic gains in productivity and innovation.”

The Biologics Formulation Workflow leverages Freeslate’s Core Module 3 (CM3) automation platform. The CM3 gives scientists a configurable system for preparing, processing and testing intricate samples including biologic formulations, biomass samples, and other complex mixtures. All of Freeslate’s integrated workflows are managed by its Lab Execution and Automation (LEA) software suite which creates a single, experimental interface that accelerates scientific decision-making. A tenured leader in the area of high throughput research, Freeslate has built strong capabilities around automated solutions addressing the complex problems of drug development.

About Freeslate, Inc.
Freeslate is a privately held company that provides products and related services for high throughput research. Based on its proprietary laboratory automation platforms, high throughput pressure reactors, and integrated Lab Execution and Analysis (LEA) software suite, the company enables dramatic gains in its customers’ productivity and innovation by delivering seamlessly integrated automation solutions. Freeslate leverages its scientific expertise through its team of Ph.D. scientists, engineers, and software developers with directly relevant experience in the industries it serves. Collaborating with customers for more than a decade, the business has provided high throughput research solutions for the pharmaceutical, chemical, energy, and consumer products industries. The company is headquartered in Sunnyvale, California, with direct sales and service in North America, Europe and Asia. For more information, visit


Share article on social media or email:

View article via:

Pdf Print

Contact Author

John Chan
Freeslate, Inc.
Email >